Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11
linical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine
Share
Why It Matters
Daré Bioscience is sharing early study results about a new cream medicine. Watch to see if doctors think the idea could work for patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.